French
DeutschICI-164384
 | |
| Clinical data | |
|---|---|
| Other names | N-n-Butyl-N-methyl-11-(3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl)undecanamide |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C34H55NO3 |
| Molar mass | 525.818 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
ICI-164384, also known as N-n-butyl-N-methyl-11-(3,17β-dihydroxyestra-1,3,5(10)-trien-7α-yl)undecanamide, is a steroidal antiestrogen and a synthetic derivative of estradiol which is closely related to fulvestrant and was never marketed.[1][2] It is a silent antagonist of the estrogen receptor (ER) with no intrinsic estrogenic activity and hence is a pure antiestrogen, unlike selective estrogen receptor modulators (SERMs) like tamoxifen.[1][2] The drug was under development by AstraZeneca for the treatment of breast cancer but was discontinued in favor of fulvestrant,[3] which is very similar to ICI-164384 but is more potent in comparison.[4]
See also
[edit]References
[edit]- ^ a b Pavlik EJ (6 December 2012). Estrogens, Progestins, and Their Antagonists: Health Issues. Springer Science & Business Media. pp. 133–. ISBN 978-1-4612-4096-9.
- ^ a b Howell A (15 October 1990). The Role of Antihormones. CRC Press. pp. 119–124. ISBN 978-1-85070-295-5.
- ^ "ICI 164384". AdisInsight. Springer Nature Switzerland AG.
- ^ Miller WR, Ingle JN (8 March 2002). Endocrine Therapy in Breast Cancer. CRC Press. pp. 64–. ISBN 978-0-203-90983-6.
External links
[edit] | This article about a steroid is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |